BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250609
DTEND;VALUE=DATE:20250612
DTSTAMP:20260515T093947
CREATED:20250304T113738Z
LAST-MODIFIED:20250304T113738Z
UID:40624-1749427200-1749686399@www.pharmajournalist.com
SUMMARY:Innovation in Psychosis Therapeutics Summit
DESCRIPTION:The Innovation in Psychosis Therapeutics Summit is the premier industry forum dedicated to advancing next-generation approaches for psychosis treatment. As 2025 marks a pivotal year for psychosis drug development—with a surge in clinical advancements and key collaborations gaining momentum—this inaugural event unites the brightest minds in biotech and pharma to overcome critical challenges in drug discovery and development. \n \nDesigned specifically for R&D leaders\, this summit is uniquely positioned to tackle the biggest hurdles in the field\, including translational validity\, patient heterogeneity\, placebo effect\, and trial scalability. By bringing together 60+ key stakeholders from discovery\, preclinical\, translational\, and clinical development\, this meeting provides a platform to collaborate\, exchange insights\, and shape the future of psychosis treatment. \nWith the growing urgency to address the significant unmet need in psychosis and the limitations of current atypical antipsychotics\, the time is now to drive innovation forward. Join the conversation as industry pioneers build on Cobenfy’s breakthrough success and explore cutting-edge strategies to develop more effective\, better-tolerated therapeutics across the psychosis spectrum. \nDon’t miss this brand-new opportunity to connect with thought leaders\, gain critical insights\, and be at the forefront of transforming psychosis R&D. \nTo know more visit: https://ter.li/9yj2vx
URL:http://www.pharmajournalist.com/event/innovation-in-psychosis-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T093947
CREATED:20250108T111946Z
LAST-MODIFIED:20250108T112021Z
UID:40293-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:7th Annual Allogeneic Cell Therapies Summit
DESCRIPTION:With the autoimmune wave breathing financial life back into the allogeneic space\, and a growing number of oncology pipelines entering the clinic\, the allogeneic community are eagerly anticipating what lies ahead! \nMaking now the ideal time to attend the 7th Annual Allogeneic Cell Therapies Summit (June 10-12 | Boston\, MA)\, your flagship forum uniting the top allogeneic developers including Atara Bio\, Adicet Bio\, Senti Bio\, Glycostem and more. \nWhat Will 2025 Offer? \n\nGround-breaking Clinical Readouts: Dive into the latest results from CAR-T therapies with Atara Bio and Adicet Bio.\nSolid Tumor Breakthroughs: Hear from Senti Bio\, NKILT Therapeutics\, and Synaptimmune on how allogeneic therapies are targeting the tumor microenvironment to unlock entirely new indications.\nManufacturing at Scale: Learn how Tevogen and Cell BioEngines are navigating the complexities of scalable\, high-quality manufacturing to make these therapies commercially viable.\nBeyond Oncology: Broaden your scope by discovering how Biosyngen and Adicet Bio are leveraging allogeneic platforms to address autoimmune disorders.\n\nAs regulatory frameworks evolve to accommodate these revolutionary therapies and investment creeps back into allogeneic development\, staying informed is no longer optional. Get involved today to be part of the conversations solving today’s challenges and shaping tomorrow’s breakthroughs. \nFind out more: https://ter.li/o21go2
URL:http://www.pharmajournalist.com/event/7th-annual-allogeneic-cell-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T093947
CREATED:20250206T124225Z
LAST-MODIFIED:20250220T125930Z
UID:40428-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:2nd Annual IMPACCT Real World Evidence Summit Europe
DESCRIPTION:This year’s IMPACCT Real World Evidence Europe conference is the only case-study led industry forum providing actionable insights into numerous challenges such as optimizing evidence generation plans in early stages\, enhancing collaboration between industry and public research to advance RWE\, consolidating cross-functional collaboration to improve effectiveness of RWE studies\, and exploring actionable study designs that empower patients to elevate RWE utility… \nAs regulators and payers increasingly elevate the importance of RWE in submission requirements and with an explosion of datasets opening up in parallel with advancing AI\, deep learning\, and large language models transforming big data analysis\, it has never been more critical to keep up with the matrix of country-specific regulatory nuances and industry case studies in optimizing integrated evidence plans\, bullet-proofing data quality\, and navigating vendor selection. \nThe 2nd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE and Evidence Generation to consolidate\, innovate and apply RWE across the drug development lifecycle\, from external control arms to reimbursement. \nWith a tight focus on leveraging AI for both efficiency gains and big data analysis\, the latest on DARWIN and using RWE to support regulatory decision-making\, and creating a robust integrated evidence strategy\, join 60+ industry pioneers from AstraZeneca\, Pfizer\, Novartis\, Sanofi and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice\, ensuring resilience and success in a dynamic landscape as a successful business partner. \nJoin us\, our speakers\, attendees and sponsors to explore strategies\, learn efficient data deployment and automation\, learn best practices for sharing real-time data and insights cross-functionally\, inform your development processes\, address biases and study product life cycle management to bridge the gap from clinical trials to real-world evidence. \nWith over 50 industry pioneers we have the force to form a comprehensive evidence plan\, break free from silos\, and bridge the gap between clinical research and practice. Get in the room with Presidents\, VPs\, Directors\, Head\, Managers and Lead Scientists all on the same mission as you. \nThis is your one opportunity to liaise with like-minded\, driven and curious individuals about industry innovation. \nTo know more visit: https://ter.li/e8cs7v
URL:http://www.pharmajournalist.com/event/2nd-annual-impacct-real-world-evidence-summit-europe/
LOCATION:Steigenberger Airport Hotel\, Amsterdam\, Stationsplein Zuid-West 951\, Schiphol\, 1117 CE\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T093947
CREATED:20250409T111953Z
LAST-MODIFIED:20250409T111953Z
UID:40897-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:Vendor Management & Outsourcing for Clinical Trials Summit
DESCRIPTION:Vendor management processes are crucial for ensuring compliance\, quality\, and timely delivery at every stage\, serving as the backbone of successful clinical trials. Acknowledging the transformative impact\, the industry is prioritizing the optimization of these intricate processes\, making significant investments to enhance key functions\, improve performance\, and maintain a competitive edge. Despite this professionals managing ancillary lab vendors and CROs lack a dedicated forum to address their unique challenges\, until now… \nIntroducing the Vendor Management & Outsourcing for Clinical Trials Summit\, built with the industry to the needs of vendor management\, outsourcing and clinical operations professionals. \nTo know more visit: https://ter.li/d1jemt
URL:http://www.pharmajournalist.com/event/vendor-management-outsourcing-for-clinical-trials-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T093947
CREATED:20250305T141309Z
LAST-MODIFIED:20250305T142300Z
UID:40667-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:4th World ADC Asia Summit
DESCRIPTION:Linking the East to the West in the ADC World | 在ADC世界连接东西方 | ADC 세계에서 동서 연결하기ADCの世界で東西をつなぐ \nIn 2025\, Asia will continue leading ADC innovation\, with growth in dual-payload ADCs\, bispecific ADCs\, and novel linker-payload technologies. Staying informed through clinical updates\, connecting with new companies\, and building collaborations will be key to seizing emerging opportunities. \nThe 4th World ADC Asia Summit (June 10-12\, 2025\, | Incheon\, South Korea)\, part of the globally recognized World ADC series\, serves as the premier platform for showcasing the latest advancements in R&D\, clinical validation\, and commercialization. \nThis industry-leading event unites Asia’s top innovators with global expertise to drive ADC success across the region. \nWhat’s New in 2025? \n Three dynamic tracks covering discovery\, preclinical\, clinical\, and CMC\nExclusive seminar days on ADC fundamentals & Bispecific ADCs – Whether you’re just starting out or a seasoned expert\, the program offers something for professionals at every level\n Unparalleled networking with leading experts and organizations \nA Global Speaker Lineup \nWith 20+ new companies joining our esteemed panel from China\, Japan\, Korea\, Taiwan\, Singapore\, the US\, and Europe—featuring industry leaders such as AstraZeneca\, AbbVie\, HoneyBear Biosciences\, Chiome Bioscience\, and more—this is a must-attend event for anyone in the ADC field. \nLearn more here: https://ter.li/iimxna
URL:http://www.pharmajournalist.com/event/4th-world-adc-asia-summit/
LOCATION:Grand Hyatt Incheon\, 208 Yeongjonghaeannam-ro 321beon-gil\, Jung-gu\, Incheon\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR